ERBB2 and non-small cell lung carcinoma: Trastuzumab is a monoclonal immunoglobulin G1 humanized murine antibody that binds to the extracellular IV domain of the HER2 receptor and, therefore, blocks its dimerization; however, studies evaluating trastuzumab efficacy have not shown a significant benefit for patients with NSCLC who overexpress the HER2 protein [97].